SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (86)6/19/2002 10:33:22 AM
From: dalroi  Respond to of 130
 
Rick

Just scanned the article
perhaps they're attracted to this

"The most common adverse event for all groups was headache. No treatment-related serious adverse events or systemic allergic reactions were reported in any group"

In the prostate carcinoma trial the fda had troubles with possible allergic reactions
Same product in women didt show that
so perhaps they plan to revive the prostae product

Cheers

Stefaan


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News